Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RO7247669 |
| Synonyms | |
| Therapy Description |
RO7247669 is a bispecific antibody that targets both PD-1 (PDCD1; CD279) and LAG3, potentially resulting in restoration of T-lymphocyte function and antitumor activity (Annals of Oncology 33 (2022): S884-S885). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RO7247669 | RO-7247669|RO 7247669|tobemstomig | LAG3 Antibody 18 PD-L1/PD-1 antibody 121 | RO7247669 is a bispecific antibody that targets both PD-1 (PDCD1; CD279) and LAG3, potentially resulting in restoration of T-lymphocyte function and antitumor activity (Annals of Oncology 33 (2022): S884-S885). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05775289 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669 | A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | DEU | BRA | BEL | AUS | 2 |
| NCT04785820 | Phase II | RO7121661 Nivolumab RO7247669 | A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | Active, not recruiting | TUR | POL | ITA | HUN | GBR | FRA | ESP | DNK | CZE | BRA | ARG | 7 |
| NCT05419388 | Phase Ib/II | RO7247669 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | Recruiting | TUR | SVK | POL | NZL | GRC | ESP | CZE | CAN | BRA | AUS | 0 |
| NCT05645692 | Phase II | Atezolizumab RO7247669 RO7247669 + Tiragolumab | A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer | Active, not recruiting | USA | TUR | POL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | BRA | AUS | 3 |
| NCT05116202 | Phase Ib/II | RO7247669 Atezolizumab + Tiragolumab Ipilimumab + Nivolumab RO7247669 + Tiragolumab | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | Completed | USA | NLD | ITA | FRA | ESP | AUS | 0 |
| NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | TUR | ISR | GBR | ESP | DNK | 5 |
CKB BOOST